The new fully human VH antibody fragment ZL-1102 developed internally by Zai Lab for the clinical phase 1b study of psoriasis reached a proof of concept

Shanghai, October 21, 2021/PRNewswire/ - Zai Lab Pharmaceutical Co.

In the efficacy data of 51 evaluable patients:

– At 4 weeks of treatment, the local psoriasis area and severity index (PASI)* score of the target skin lesions in the ZL-1102 group showed a relative improvement of about 45% higher than that of the placebo group

– The anti-inflammatory effect of ZL-1102 was observed in the study, including the obvious improvement of target skin lesion erythema within 4 weeks, and it can be maintained until the 6th week of the study after the end of treatment

– The ZL-1102 group showed continuous clinical improvement in the target skin lesion area (decreased skin lesion area), compared to the placebo group with an increase in skin lesion area during treatment

– ZL-1102 continues to show a higher response rate than placebo for 4 weeks, and can maintain the response until the 6th week of the study after the end of treatment

The safety data of 53 evaluable patients showed:

– ZL-1102 is safe and well tolerated, comparable to placebo, and the number of adverse events during treatment is small and mild

– Pharmacokinetic studies confirmed that this product has no systemic absorption and exposure

The main investigator of the study, Professor Rodney Sinclair, Director of Dermatology at Epworth Hospital, Professor of Dermatology at the University of Melbourne, and Director of Sinclair Dermatology Hospital, said: “This proof-of-concept study is a multi-center study conducted in Australia

Dr.

Dr.

* The local PASI score is a subset of the overall PASI score, and the area score is not included in the calculation

Conference call and webcast information

Zai Lab will hold a related conference call at 8 am Eastern Standard Time on October 21 (8 pm Beijing time)

You can visit our website http://ir.

– Registration link: http://apac.

– Conference ID: 5549559

Webcast link: https://edge.

All participants need to use the above link to complete the online registration before the conference call

The replay will be provided after the conference call.
You can visit our website http://ir.
zailaboratory.
com to watch the replay
.

About ZL-1102

ZL-1102 is a new fully human VH antibody fragment in the research stage that targets IL-17A cytokines and is generated by Crescendo Biopharmaceutical's proprietary Humabody® VH platform
.
It is formulated as a hydrogel for the topical treatment of chronic plaque psoriasis
.
Because this type of molecule is small in size and has other unique characteristics, it has higher target affinity and tissue permeability than full-length monoclonal antibodies
.
Due to the potential for better safety and tolerability, this topical treatment product is expected to expand the use of existing IL-17 targeted therapies to a large population of patients with chronic plaque psoriasis with less severe symptoms
.

About ZL-1102 proof-of-concept research

This proof-of-concept clinical phase Ib study consists of two parts
.
Open label Part A evaluated the pharmacokinetic properties of a single dose of ZL-1102 in six patients with mild to moderate chronic plaque psoriasis
.
In Part B of the double-blind, placebo-controlled, multi-center study, 53 mild to moderate patients were randomly assigned to the ZL-1102 topical treatment group or the placebo group twice a day.
The primary endpoint was to evaluate the safety of ZL-1102 , Pharmacokinetic properties and efficacy
.
The primary efficacy endpoint in Part B is the percentage change in the local PASI score from baseline on day 29
.
Secondary endpoints include changes in individual indicators of the local PASI score from baseline, target skin lesion size, and response rate
.
Zai Lab plans to release the complete data of the study and plan to publish the article at a recent academic conference
.

About mild to moderate chronic plaque psoriasis

Plaque psoriasis is a common chronic, systemic, and inflammatory autoimmune skin disease characterized by the appearance of red plaques with silver scales on the skin
.
Psoriasis affects approximately 125 million people worldwide
.
Among them, 80-90% are plaque psoriasis, which is the most common type of psoriasis
.
70-80% of plaque psoriasis cases are mild to moderate, and IL-17 inhibitors that have been marketed are currently not suitable for such cases
.
Local treatment is the standard treatment for mild to moderate plaque psoriasis
.
However, current treatment options have limited efficacy or long-term use has safety issues
.

About Zai Lab

Zai Lab (Nasdaq stock code: ZLAB; Hong Kong Stock Exchange stock code: 9688) is a patient-centric, innovative global biopharmaceutical company in the commercialization stage, committed to the development and Commercially solve the unmet medical needs in the fields of oncology, autoimmunity and infectious diseases
.
To achieve this goal, the company's experienced team has established strategic cooperation with the world's leading biopharmaceutical companies to build a broad product pipeline composed of innovative drugs
.
Zai Lab has established an internal team with strong drug R&D and translational research capabilities, and is building a pipeline of drug candidates with international intellectual property rights
.
Our vision is to become a leading global biopharmaceutical company that develops, produces and sells innovative products, and strives to promote the health and well-being of people all over the world
.

For more information about the company, please visit or follow the company's LinkedIn account: https:// and WeChat public account: Zai Lab
.

Source: Zai Lab